Back to Search
Start Over
Diabetes Treatment with Dapagliflozin and Its Combinations: Insights from Clinical Practice.
- Source :
- Journal of Diabetology: Official Journal of Diabetes in Asia Study Group; Apr-Jun2024, Vol. 15 Issue 2, p183-194, 12p
- Publication Year :
- 2024
-
Abstract
- Objective: To evaluate the perception of clinicians about the association of heart failure (HF) and type 2 diabetes mellitus (T2DM) and the utilization of dapagliflozin-based combination therapies for cardiorenal protection in Indian patients with T2DM. Materials and Methods: This cross-sectional, digital questionnaire-based study involved diabetologists and consulting clinicians from pan-India and was conducted between October 2022 and March 2023. Results: Of the 982 clinicians, 871 completed the study. According to 90.93% and 47.19% of clinicians, most patients with T2DM were in the age group of 40–60 years, and cardiovascular (CV) risk is present in 3 in 10 of T2DM patients, respectively. As the initial choice of oral antidiabetic class (other than metformin), 43.86% of clinicians preferred sodium-glucose cotransporter-2 inhibitors (SGLT2i). Dapagliflozin is the most effective SGLT2i in reducing mortality/hospitalization in T2DM patients with HF (70.38%). In T2DM patients with CV/renal risk, 66.02% of clinicians recommended dapagliflozin with sitagliptin (10 mg + 100 mg strength) as SGLT2i plus dipeptidyl peptidase-4 inhibitors (DPP4i) fixed-dose combination (FDC). The use of a triple-drug FDC of dapagliflozin plus sitagliptin plus metformin was strongly recommended by 74.40% of clinicians. Early initiation and intensification with a combination of SGLT2i and DPP4i in young T2DM patients (30–50 years) inadequately managed on metformin was highly recommended (94.58%). The majority of clinicians opined that SGLT2i should be initiated in all T2DM patients with comorbidities to prevent HF complications (97.58%), and SGLT2i is underutilized in India for the treatment of HF in T2DM patients (89.21%). Conclusion: The overall observations provide insights into the usage patterns of dapagliflozin-based combination therapies for cardiorenal protection among Indian T2DM patients. [ABSTRACT FROM AUTHOR]
- Subjects :
- KIDNEY disease risk factors
COMBINATION drug therapy
HEALTH literacy
CROSS-sectional method
METFORMIN
GLYCOSYLATED hemoglobin
RESEARCH funding
DAPAGLIFLOZIN
SCIENTIFIC observation
QUESTIONNAIRES
HOSPITAL care
PHYSICIANS' attitudes
HEART failure
CARDIOVASCULAR diseases risk factors
TYPE 2 diabetes
PHYSICIANS
DIABETES
COMORBIDITY
DISEASE complications
Subjects
Details
- Language :
- English
- ISSN :
- 25433288
- Volume :
- 15
- Issue :
- 2
- Database :
- Complementary Index
- Journal :
- Journal of Diabetology: Official Journal of Diabetes in Asia Study Group
- Publication Type :
- Academic Journal
- Accession number :
- 178054115
- Full Text :
- https://doi.org/10.4103/jod.jod_115_23